{"entity":{"id":"nct06623656","kind":"trial","name":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC","aka":[],"tldr":"A phase 2 trial of cemiplimab in lung cancer, run by Weill Medical College of Cornell University, now recruiting.","summary":"Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC is a phase 2, randomised interventional study registered as NCT06623656 by Weill Medical College of Cornell University, with a registry enrolment figure of 112 participants, started 2025-02-21 and due to reach its primary completion in 2026-12. Interventions recorded: Cemiplimab; Platinum based chemotherapy; Stereotactic body radiation therapy. Conditions listed: Carcinoma, Non-Small-Cell Lung. Primary outcome: Number of participants with pathological complete response (pCR). Lung eligibility wording from the registry: \"Patients with histologically or cytologically proven clinical stages IB (T2aN0), II, and III(N2) NSCLC (according to AJCC version 9) eligible for surgical resection with curative intent\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06623656","url":"https://clinicaltrials.gov/study/NCT06623656"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["resectable-nsclc"],"sections":[],"technologies":["checkpoint-inhibitor","sbrt"],"targets":[],"drugs":["cemiplimab"],"companies":["regeneron"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06623656","phase":"2","setting":"Multicenter Randomized Phase II Trial of Neoadjuvant Radioimmunotherapy Versus Chemoimmunotherapy in Patients With Clinical Stages IB-III (N2) Non-small Cell Lung Cancer","sponsor":"Weill Medical College of Cornell University","enrolled":112,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06623656/","neighbours":{"cancer":[{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"drug":[{"id":"cemiplimab","kind":"drug","name":"Cemiplimab","route":"/drugs/cemiplimab/"}],"company":[{"id":"regeneron","kind":"company","name":"Regeneron","route":"/companies/regeneron/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}